Tissue Factor, human
|Antibody||Host||Catalogue No.||Size||Product Insert|
|Purified IgG||Sheep||SATF-IG||10 mg|
|Peroxidase conjugated IgG||Sheep||SATF-HRP||0.2 mg|
|Murine monoclonal, FITC conjugated IgG||Murine||MATF-FITC||0.1 mg|
|Murine monoclonal, biotinylated IgG||Murine||MATF-BIO||0.1 mg|
MATF-FITC – Flow Cytometry application
Description of Factor VII
Description of Tissue Factor (TF)
Tissue Factor (TF) is an integral membrane glycoprotein expressed in the plasma membranes of many cell types. It is a single chain molecule of 44 kDa consisting of an extra-cellular domain (residues 1-219), a trans-membrane domain (residues 220-242) and the C-terminal intracellular domain of residues 243-263. Most abundant in the tissue adventitia, TF becomes exposed to blood at the site of vascular injury. The availability of TF is important in initiating coagulation by acting as a receptor for both the zymogen and protease forms of plasma factor VII (FVII and FVIIa), as well as mediating the conversion of bound FVII to FVIIa. The binding of FVII to TF in the presence of a negatively charged surface such as a phospholipid (or cell surface) promotes the auto activation of FVII by FVIIa. The TF-FVIIa complex in the presence of calcium ions proteolytically activates factors IX and X. These enzyme products are then capable of activating FVII to FVIIa by feedback amplification. The activity of TF-FVIIa activity is regulated by a TFPI (tissue factor pathway inhibitor), a member of the Kunin superfamily of protease inhibitors. TFPI contains three kunitz domains and is able to bind and inhibit the TF-FVIIa complex in the presence of activated factor X and calcium ions. Antithrombin has also been reported to inhibit FVIIa activity in the presence of TF and heparin. Although a membrane protein, low levels of TF products have been demonstrated in plasma. Increased levels of circulating TF products may be a risk factor for thrombotic disease 1-4.
1. Nemerson Y; in Hemostasis and Thrombosis, 3rd Edition, eds. RW Colman, J Hirsh, VJ Marder and EW Salzman, pp. 81-93, J.B. Lippincott Co., Philadelphia, 1994.
2. Neuenschwander PF, Morrissey JH; Deletion of the Membrane Anchoring Region of Tissue Factor Abolishes Autoactivation of F.VII but not Cofactor Function. JBC 267, pp 14477-14482, 1992.
3. Lawson LH, Butenas S, Mann KG; The Evaluation of Complex-dependent Alterations in Human Factor VIIa. JBC 267, pp 4834-4843, 1992.
4. Sambola A, Osende J, Hathcock J, Degen M, Nemerson Y, Fuster V, Crandall J, Badimon JJ; The Role of Risk Factors in the Modulation of Tissue Factor Activity and Blood Thrombogenicity. Circulation 107, pp 973-977, 2003.
SATF-IG Sheep anti-human TF, whole IgG from antiserum
SATF -HRP Sheep anti-human TF, IgG-peroxidase conjugate